IMUNON (IMNN) announced that new translational data from the Phase 2 OVATION 2 Study of IMNN-001, its investigational therapy for the treatment of women with newly diagnosed advanced ovarian cancer, will be presented at the American Association for Cancer Research, AACR, Special Conference in Cancer Research: Advances in Ovarian Cancer Research, being held September 19-21, 2025, in Denver, Colorado. IMNN-001, based on IMUNON’s proprietary TheraPlas technology platform, is an interleukin-12 DNA plasmid vector incorporated into a novel nanoparticle delivery system, enabling cell transfection followed by persistent, local production and secretion of the IL-12 protein in the tumor microenvironment.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMNN:
- Imunon Regains Nasdaq Compliance with Bid Price Requirement
- Imunon regains compliance with Nasdaq min bid price listing requirement
- Imunon, Inc. Advances Phase 3 Trial for Innovative Cancer Treatment
- Imunon, Inc.’s Phase II Study on IMNN-001: A Potential Game-Changer in Ovarian Cancer Treatment?
- Imunon, Inc.’s Ongoing Clinical Trial: Potential Game-Changer for Ovarian Cancer Treatment?